Efgartigimod showed higher independent walking at week 4 and running at week 12 versus IVIG in GBS patients unable to walk.

This single-center retrospective study assessed the efficacy of efgartigimod compared with intravenous immunoglobulin (IVIG) in 34 patients with Guillain-Barré syndrome who were unable to walk independently. The primary outcomes measured the proportion of patients able to walk independently at week 4 and able to run at week 12. Safety and tolerability were also evaluated, though specific adverse event data were not reported.

Regarding the ability to walk independently at week 4, 100% of patients in the efgartigimod group achieved this milestone compared with 64% in the IVIG group. The difference was statistically significant with a p-value of 0.03. At week 12, the proportion of patients able to run was 100% in the efgartigimod group versus 55% in the IVIG group, with a p-value of 0.006. Secondary outcomes included clinical improvement in patients with ophthalmoplegia and respiratory insufficiency.

Tolerability was described as favorable, while data on adverse events, serious adverse events, and discontinuations were not reported. Key limitations include the single-center design and the retrospective nature of the study. These preliminary findings need validation in larger prospective studies before definitive conclusions can be drawn regarding the clinical utility of efgartigimod over IVIG for this population.